Robert J. Palmisano
Known title: DirectorCIK: 0001138646
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| AEON | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| AEON | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| RXST | ▲ Buy | Grant | 8,624 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.